[go: up one dir, main page]

MX2019001007A - Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades. - Google Patents

Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.

Info

Publication number
MX2019001007A
MX2019001007A MX2019001007A MX2019001007A MX2019001007A MX 2019001007 A MX2019001007 A MX 2019001007A MX 2019001007 A MX2019001007 A MX 2019001007A MX 2019001007 A MX2019001007 A MX 2019001007A MX 2019001007 A MX2019001007 A MX 2019001007A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
gzd824
acceptable salts
treating diseases
novel application
Prior art date
Application number
MX2019001007A
Other languages
English (en)
Inventor
Ye Wei
Li Peng
Lu Xiaoyun
Ding Ke
Original Assignee
Healthquest Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healthquest Pharma Inc filed Critical Healthquest Pharma Inc
Publication of MX2019001007A publication Critical patent/MX2019001007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe el uso de (3-((1H-pirazol[3,4-b]pir idin-5-sustituida)etinil)-4-metil-N-(4-((4-metilpiperazin-1-susti tuida)metil)-3-(trifluorometil)fenil)benzamida) y una sal farmacéuticamente aceptable de la misma en la elaboración de un medicamento para el tratamiento contra la leucemia linfoblástica aguda, en particular, la leucemia linfoblástica de linfocitos B precursores.
MX2019001007A 2016-07-25 2017-04-20 Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades. MX2019001007A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610592371 2016-07-25
CN201611040298.4A CN106580993B (zh) 2016-07-25 2016-11-11 耐克替尼及其药学上可接受的盐在治疗疾病中的新的应用
PCT/CN2017/081173 WO2018018950A1 (zh) 2016-07-25 2017-04-20 耐克替尼及其药学上可接受的盐在治疗疾病中的新的应用

Publications (1)

Publication Number Publication Date
MX2019001007A true MX2019001007A (es) 2019-06-10

Family

ID=58592880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001007A MX2019001007A (es) 2016-07-25 2017-04-20 Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.

Country Status (10)

Country Link
US (3) US20200330456A1 (es)
EP (1) EP3488850B1 (es)
JP (1) JP6724240B2 (es)
KR (1) KR20190032425A (es)
CN (1) CN106580993B (es)
AU (1) AU2017303624A1 (es)
CA (1) CA3031852A1 (es)
IL (1) IL264407A (es)
MX (1) MX2019001007A (es)
WO (1) WO2018018950A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111035641B (zh) * 2018-10-11 2022-04-12 暨南大学 Gzd824及其药学上可接受的盐在治疗疾病中的新应用
DK3713576T3 (da) * 2018-12-03 2025-08-18 Ascentage Pharma Suzhou Co Ltd Forbindelse med formel (i) og ponatinib til brug ved behandling af kronisk myeloid leukæmi med bcr-abl-mutationer
CN110917157B (zh) * 2020-01-21 2020-06-16 上海亚盛医药科技有限公司 含炔基化合物的药物组合物、其制备方法及应用
US20230078120A1 (en) * 2020-05-04 2023-03-16 Ascentage Pharma (Suzhou) Co.,Ltd. Methods for Treating Coronavirus Infections
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101885722B (zh) * 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
US8846671B2 (en) * 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
CN103539784B (zh) * 2012-07-09 2016-08-17 中国科学院广州生物医药与健康研究院 杂环苯甲酰胺类化合物、药用组合物及其应用

Also Published As

Publication number Publication date
CA3031852A1 (en) 2018-02-01
WO2018018950A1 (zh) 2018-02-01
US20250170125A1 (en) 2025-05-29
AU2017303624A1 (en) 2019-02-14
CN106580993A (zh) 2017-04-26
EP3488850A1 (en) 2019-05-29
US20200330456A1 (en) 2020-10-22
JP6724240B2 (ja) 2020-07-15
JP2019522019A (ja) 2019-08-08
EP3488850A4 (en) 2020-08-26
EP3488850B1 (en) 2024-06-19
CN106580993B (zh) 2018-11-30
KR20190032425A (ko) 2019-03-27
US20210228573A1 (en) 2021-07-29
IL264407A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2019001007A (es) Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
CY1118340T1 (el) Αναστολεις κινασης
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
HK1245078A1 (zh) 治疗神经退行性疾病的方法
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
EA201792116A1 (ru) Ингибитор янус-киназы
PH12020550452A1 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP2014062126A5 (es)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
ECSP18051143A (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CY1121988T1 (el) Θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
PH12014501278A1 (en) Kinase inhibitors
TN2016000489A1 (en) Carboxamide derivatives.
CL2007002366A1 (es) Sales maleato, tosilato, fumarato y oxalato de 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida; proceso de preparacion de dichas sales, utiles para el tratamiento de afecciones
JP2015516419A5 (es)
EA201692298A1 (ru) Производные карбоксамидов
IL283823A (en) 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease
JP2016530242A5 (es)
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения